Sunday, July 27, 2014

Did we come from monkeys?

Where we came from" is as important of a topic as "where are we going?"
In 1859 with the publication of the famous book Origin of the Species Charles Darwin would forever change the way our modern world looked at the issue of origins.
His theory concluded that the biblical account of creation was false, that there was no intelligent designer, and that our universe and life was nothing more than a series of accidental mutations over billions of years.
More than anyone else, Darwin was responsible for giving a credible story of origins that left God out. Man was no longer a creation of God, but a more highly evolved monkey.
Christians who still believe in the biblical account of creation are often accused of "ignoring scientific evidence" and accepting creation with "blind faith". But this statement is simply not true.
In fact, there is a growing body of scientists, both Christian and non-Christian, who have found the theory of evolution to have gaping holes and scientifically impossible explanations that require a huge amount of "blind faith".
Science is the discipline of comprehending and systematising knowledge by observation and experiment. Theories are established that must be tested, re-tested and re-tested.
Scientists will establish theories, conduct experiments, and then observe the results to see if their theories were correct. The theory of evolution must submit itself to the same scientific scrutiny.
One of the many "giant leaps" proposed by evolutionists is that living matter spontaneously evolved from non living matter. Their theory is that at some point in the distant past, there was no life on Earth just non living matter.
It is hypothesised that there existed on Earth a "primordial soup" with just the right chemicals and atmospheric conditions and that life was "spontaneously generated". Mind you, no scientist has ever been able to prove this theory by experiment or observation in a laboratory. We are just told to "accept it" with no evidence. Sounds like blind faith!
In the 1970s, a British astronomer by the name of Sir Fredrick Hoyle calculated the mathematical probability that life could be spontaneously generated from this "primordial soup".
Hoyle and his associates knew that the simplest form of life on Earth was a bacterium which required at least 2000 independent functioning proteins in order to not only "exist" but to metabolise and reproduce.
Hoyle calculated the probability of the spontaneous generation of just the proteins of a single amoeba at 1 in 1040,000. If you think that is amazing, Hoyle hadn't even added to the calculations the odds of the spontaneous generation DNA or RNA or the cell walls etc. How complex is DNA?
Harvard University in 2012 reported that they were able to store 700 terabytes of data in a single gram of DNA. That is the equivalent of 14,000 fifty gigabyte blue ray discs.
The odds that DNA spontaneously generated with that level of complexity is so ridiculous that it is virtually impossible. But those are just the odds of spontaneous generation. Add to that, the odds that trillions of accidental mutations over time would give us the amazingly complex living systems of today, and you are really living on "blind faith".
But what is so significant is that if the theory of evolution is true, then the Bible cannot be true.
The book of Genesis, which gives us God's account of the creation of the universe, the earth, living matter and mankind, would all be false if the theory of evolution is true.
Before you discard the Bible as a work of fiction in favour of evolution, and before you tell your children that they are nothing more than a highly evolved monkey, put evolution to the test!
The theory of evolution has been responsible for a massive decline in morality in the world.
Once you convince a society that there is no God, that all religion is fiction or a coping mechanism, you also destroy the basis for morality. Read carefully Romans 1:17-32 and see God's warning about the demoralising of society without God!
The Creation Science Conference being held July 28 - August 1, 2014, is an opportunity for you to consider the scientific reasons that proponents of intelligent design believe evolution is not only false, but impossible.
You will be presented with evidence that reveals a wise, intelligent creator is responsible for the grandeur of the universe, not some unexplainable "Big Bang". By the end of the week you can answer for yourself, "Is the Bible a credible record of our origins?"
Perhaps our educational department will consider allowing "intelligent design" to be presented to the same degree as theory of evolution in our schools.
For more information contact Pastor Kory Mears on kory.mears@gmail.com.
* Pastor Mears was the pastor of Nausori Baptist Church for 17 years and is the Principal of Nausori Baptist Christian Academy for 11 years

Saturday, July 26, 2014

Why cold-blooded animals don’t need to wrap up to keep warm

By Anwesha Ghosh, University of Rochester
Animals have evolved to occupy almost all corners of the Earth. To survive, no matter the weather outside, they all need temperature-sensitive bodily reactions to work. This is easy for warm-blooded animals, such as humans, because they have the ability to maintain their body temperature.
But cold-blooded animals can’t do that. When the weather changes and the mercury swings one way, their cells get exposed to that change in temperature. Yet cold blooded animals survive just fine. Michael Welte, associate professor of biology at the University of Rochester, may have just discovered how. His team’s findings have been published in the Journal of Cell Biology.

At the molecular level, the key to survival is to ensure that proteins are being made at the right time and in the right amount. To do that every cell in the body has an assembly line. This is partly driven by motor proteins, which act like cargo trains delivering the messenger molecule RNA that comes from DNA located in the cell’s nucleus. RNA needs to reach the end of the assembly line where special organelles, called ribosomes, decode the message and make the protein.
“We have found a molecule that keeps protein production balanced when temperatures change,” said Welte. “It happens to do so by controlling cellular transport.”
Theirs was a serendipitous discovery. They were studying fruit flies, which happen to be cold blooded, when they found that making some proteins is difficult for the flies when temperatures change.
As temperatures fall, the protein assembly line slows down more than the cargo trains. This creates an imbalance where, when the motor proteins reach the ribosomes, if the messenger RNA molecules are not used up immediately, they could be lost forever. This could throw the cell completely off-balance, stopping protein synthesis altogether.
But Welte found a special protein, called Klar, that keeps the balance intact. Klar behaves like the emergency brakes of the cargo trains. As soon as the mercury level falls, Klar slows down the motor proteins carrying messenger RNA molecules. Now that the pace of delivery of the blueprints matches the rate of making proteins, the assembly line stays balanced.
In fruit flies, Welte found that the protein assembly line balance is especially important for making a protein called Oskar. Egg cells, from which a fruit fly will hatch, produce Oskar. In the egg cell that still has not decided its orientation, Oskar accumulates and defines where the posterior end will be. The posterior end of the cell will later give rise to the tail after hatching. If Oskar is not made properly that the eggs will not be able to hatch.
When Welte used genetic tools in fruit flies to remove Klar from the cell, he found that losing Klar had no effects on the baby flies that hatched at normal temperature. But as soon as the temperature was lowered, the eggs could not hatch. Development of the fruit fly is completed at colder temperatures only when Klar is present in the egg cell.
Klar is found in all insects in the animal kingdom, where Welte thinks that Klar might be playing a similar role. It would also be interesting to find a similar protein in other cold-blooded animals.
Body temperature in humans does not fluctuate as much as it does in flies. But, with fevers and other conditions, our cells could be exposed to fluctuations in temperature as well. Welte speculates that a similar mechanism could be taking place in our cells as well, keeping our protein production stable. “While we don’t have the Klar protein in our cells, the mechanism for producing proteins is very similar,” Welte said.
The Conversation
By Anwesha Ghosh, University of Rochester
Anwesha Ghosh does not work for, consult to, own shares in or receive funding from any company or organisation that would benefit from this article, and has no relevant affiliations.

Friday, July 25, 2014

Drug Spurs Latently Infected Cells But Doesn’t Taper HIV Reservoir

Romidepsin, a cancer drug from the HDAC inhibitor class, awakened HIV-infected immune cells from their latent state, but it did not ultimately shrink the size of the viral reservoir in a small safety and efficacy trial, aidsmap reports. Ole Schmeltz Søgaard, MD, of Aarhus University Hospital in Denmark, presented findings from the Phase I/II clinical trial at the 20th International AIDS Conference (AIDS 2014) in Melbourne, Australia.

The trial gave three weekly injections of romidepsin to five men and one woman living with HIV. All of the participants were taking antiretrovirals (ARVs) and had an undetectable viral load at the study’s outset. 

There were various indications that romidepsin was succeeding in reversing latency of HIV-infected cells and causing them to begin replicating virus again (this makes them susceptible to ARVs, which cannot combat dormant virus). The drug apparently increased histone H3 acetylation in immune cells, an effect that increased with each dose. This essentially means that the drug was indeed inhibiting enzymes that keep HIV tightly wound within an immune cell’s nucleus. Meanwhile, the levels of cell-associated HIV RNA in CD4s rose in all the participants; each successive dose led to a larger increase. The viral load in plasma also increased, to the level of detectability with a standard viral load test in five of the participants. The composition of CD4 and CD8 cells shifted so that there were more naive cells and fewer effector and central memory cells. Both types of immune cells exhibited reduced expression of a marker signaling cell exhaustion.

However, readings of the total HIV DNA found in the participants’ CD4 cells showed no significant change, suggesting that romidepsin apparently didn’t diminish the size of the viral reservoir.

The drug proved generally safe and well tolerated. The most common side effects were nausea, other gastrointestinal problems and fatigue.

In April 2013, news of Søgaard’s work on HDAC inhibitors led to a frenzy of inaccurate reporting in the popular press claiming that scientists were “within months” of a cure. http://www.aidsmeds.com/articles/misleading_reports_1667_23916.shtm

Surprise: Only 8.2% of Human DNA Is Functional

Surprise: Only 8.2% of Human DNA Is Functional
Source: © beawolf - Fotolia.com
  • Oxford University scientists report that only 8.2% of human DNA is likely to be doing something important, i.e., is functional. This number is quite different from one given in 2012, when a number of researchers involved in the ENCODE (Encyclopedia of DNA Elements) project stated that 80% of our genome has some biochemical function.
    According to the Oxford team, which published its study (“8.2% of the Human Genome Is Constrained: Variation in Rates of Turnover across Functional Element Classes in the Human Lineage”) in PLOS Genetics, the 80% claim has been controversial, with many in the field arguing that the biochemical definition of 'function' was too broad—that just because an activity on DNA occurs, it does not necessarily have a consequence. For functionality you need to demonstrate that an activity matters.
    To reach their figure, the Oxford University group took advantage of the ability of evolution to discern which activities matter and which do not. They identified how much of our genome has avoided accumulating changes over 100 million years of mammalian evolution—a clear indication that this DNA matters; it has some important function that needs to be retained.
    “Constrained DNase 1 hypersensitivity sites, promoters, and untranslated regions have been more evolutionarily stable than long noncoding RNA loci, which have turned over especially rapidly,” wrote the investigators. “By contrast, protein coding sequence has been highly stable, with an estimated half-life of over a billion years (d1/2 = 2.1–5.0). From extrapolations we estimate that 8.2% (7.1–9.2%) of the human genome is presently subject to negative selection and thus is likely to be functional, while only 2.2% has maintained constraint in both human and mouse since these species diverged. These results reveal that the evolutionary history of the human genome has been highly dynamic, particularly for its noncoding yet biologically functional fraction.”
    “This is in large part a matter of different definitions of what is 'functional' DNA,” says joint senior author Chris Pointing, Ph.D., of the MRC Functional Genomics Unit at Oxford University. “We don't think our figure is actually too different from what you would get looking at ENCODE's bank of data using the same definition for functional DNA.”
    “But this isn't just an academic argument about the nebulous word function. These definitions matter. When sequencing the genomes of patients, if our DNA was largely functional, we'd need to pay attention to every mutation. In contrast, with only 8% being functional, we have to work out the 8% of the mutations detected that might be important. From a medical point of view, this is essential to interpreting the role of human genetic variation in disease.”
    The researchers used a computational approach to compare the complete DNA sequences of various mammals, from mice, guinea pigs, and rabbits to dogs, horses, and humans. Gerton Lunter, Ph.D., from the Wellcome Trust Centre for Human Genetics at Oxford University, the other joint senior author, explained: “Throughout the evolution of these species from their common ancestors, mutations arise in the DNA and natural selection counteracts these changes to keep useful DNA sequences intact.”
    The rest of the human genome, the non-8.2%, is leftover evolutionary material, parts of the genome that have undergone losses or gains in the DNA code, often called “junk” DNA.

Stomach cancer has four subtypes, say scientists

Scientists belonging to a US research network have found there are four distinct molecular subtypes of stomach cancer, also referred to as gastric cancer or gastric adenocarcinoma. They believe the discovery will change how researchers and clinicians view stomach cancer, enabling treatments to be tailored to individual patients, according to the specific genetic features of their tumors.
The researchers, who report their findings in the journal Nature, are members of The Cancer Genome Atlas (TCGA), a group of scientists in the US that formed in 2005 and is characterizing the genomes of more than 30 types of cancer.
Stomach cancer is a leading cause of cancer-related deaths worldwide - estimates suggest around 723,000 people die of the disease every year. In the US, the American Cancer Society estimate that in 2014, about 22,220 people will be diagnosed with the disease, and about 10,990 will die of it.

New system based on molecular features instead of cell and tissue characteristics

The current system for classifying stomach cancer puts it into two groups: diffuse and intestinal. The system uses mainly changes in cell and tissue to distinguish them. The researchers note that it is not easy to classify gastric cancer using this system because cancer cells can look quite different under the microscope, even when they are from the same tumor.
Adam Bass, assistant professor in the Department of Medicine at Harvard Medical School, Boston, MA, was one of the lead investigators on the study. He explains the advantage of the new classification system:

"A key advance with this project is that we have identified and developed a much more useful classification system to find groups of gastric cancer that have distinct molecular features, and at the same time, we also identified key targets to pursue in different groups of patients."
"This will provide a strong foundation for categorizing the disease and for doing so in a way in which we can develop clinical trials based on some of the critical molecular alterations that are driving different classes of cancers," he adds.
In the study, Prof. Bass and colleagues carried out complex statistical analyses of molecular features from 295 tumors. The analyses used six types of genetic data, including DNA sequencing, RNA sequencing and protein arrays.

Four subgroups of stomach cancer

They concluded there are four subgroups of stomach cancer:
  • Type 1, representing 9% of the tumors they analyzed, were positive for Epstein-Barr virus (EBV) and had several other molecular features in common.
  • Type 2 (22% of tumors) showed high level of "microsatellite instability" or MSI, where mutations tend to accumulate in repeated sequences of DNA.
  • Type 3 (20%) were classed as genomically stable because they showed a low level of somatic copy number alterations (SCNAs) - which can result from duplication or deletion of sections of the genome.
  • Type 4 (50% of tumors) were classed as chromosomally unstable, because they showed a high level of SCNAs.
DNA magnifying glass
Through their research, the team identified four molecular subtypes of stomach cancer, which could help them tailor treatment to individual patients, according to the specific genetic features of their tumors.
The researchers were particularly interested in the group that was positive for EBV, which in the US is best known as the cause of infectious mononucleosis or glandular fever. EBV is also believed to cause some cancers, including nasopharyngeal carcinoma, a type of head and neck cancer, and some types of lymphoma.
EBV has been found in a small minority of stomach cancers that also express EBV genes in their tumors. But this study also links EBV in gastric tumors to other molecular features.
For example, one of the molecular features they found in EBV-positive tumors was a tendency for higher rates of PIK3CA gene mutations. This gene codes for a protein called PI3-kinase that is important for cell growth and division, and other cell functions relevant to cancer.
Such a discovery might indicate that stomach cancers positive for EBV might respond to PI3-kinase inhibitors, says the team. These drugs are currently in the early stages of clinical trials in the US.
The team also made interesting discoveries in the other three subgroups. For example, tumors of the genomically stable subtype showed frequent mutations in the gene RHOA, whose protein interacts with other cell proteins to help cells change shape and migrate - this can be an important feature in tumor growth.
Also, chromosomally unstable tumor types showed frequent amplifications of genes that code for receptor proteins that are linked to abnormal cell growth. Drugs are already in use that might curb their activity, says the team.
TCGA is jointly managed by the National Human Genome Research Institute (NHGRI) and the National Cancer Institute (NCI), both within the National Institutes of Health (NIH).
Meanwhile, Medical News Today recently learned of another study where DNA work offers clues for stomach cancer research. Writing in Nature Communications, researchers from the Genome Institute of Singapore explain how they developed a technology that shows how genes in healthy stomach cells are altered when they become cancerous.
Written by

Intracellular RNA-Seq. This literature review highlights a study led by George Church describing FISSEQ, or fluorescent in situ RNA sequencing

Intracellular RNA-Seq
FISSEQ appears to be sensitive to genes associated with cell type and function, and this in turn could be used for cell typing. [© Alila Medicinal Media - Fotolia.com]




  • Methods such as fluorescence in situ hybridization (FISH) allow gene expression to be observed at the tissue and cellular level; however, only a limited number of genes can be monitored in this manner, making transcriptome-wide studies impractical. George Church's group* is presenting the further development of their original approach called fluorescent in situ sequencing (FISSEQ) to incorporate a spatially structured sequencing library and an imaging method capable of resolving the amplicons (see Figure 1).
    In fixed cells, RNA was reverse transcribed with tagged random hexamers to produce cDNA amplicons. Aminoallyl deoxyuridine 5-triphosphate (dUTP) was incorporated during reverse transcription and after the cDNA fragments were circularized before rolling circle amplification (RCA), an amine-reactive linker was used to cross-link the RCA amplicons containing aminoallyl dUTP. The team generated RNA sequencing libraries in different cell types, tissue sections, and whole-mount embryos for three-dimensional (3D) visualization that spanned multiple resolution scales (see Figure 1).
  • Click Image To Enlarge +
    Figure 1
    Figure 1. Construction of 3D RNA-seq libraries in situ. After RT using random hexamers with an adapter sequence in fixed cells, the cDNA is amplified and cross-linked in situ. (A) A fluorescent probe is hybridized to the adapter sequence and imaged by confocal microscopy in human iPS cells (hiPSCs; scale bar: 10 μm) and fibroblasts (scale bar: 25 μm). (B) FISSEQ can localize the total RNA transcriptome in mouse embryo and adult brain sections (scale bar: 1 mm) and whole-mount Drosophila embryos (scale bar: 5 μm), although we have not sequenced these samples. (C) 3D rendering of gene-specific or adapter-specific probes hybridized to cDNA amplicons. 3D, three-dimensional; RT, reverse transcription; FISSEQ, fluorescent in situ sequencing; FISH, fluorescence in situ hybridization.
  • In a proof-of-concept experiment (see Figure 2) the authors sequenced primary fibroblasts in situ after simulating a response to injury, which yielded 156,762 reads, mapped to 8,102 annotated genes. When the 100 highest ranked genes were clustered, cells kept in fetal bovine serum medium were enriched for fibroblast-associated gene hits, while the rapidly dividing cells in epidermal growth factor medium were less fibroblast-like, reaffirming that the FISSEQ platform output reflects the change in transcription status as a function of the cellular environment and stress factors.
  • Click Image To Enlarge +
    Figure 2
    Figure 2. Overcoming resolution limitations and enhancing the signal-to-noise ratio. Ligation of fluorescent oligonucleotides occurs when the sequencing primer ends are perfectly complementary to the template. Extending sequencing primers by one or more bases, one can randomly sample amplicons at 1/4th, 1/16th, and 1/256th of the original density in fibroblasts (scale bar: 5 μm). N, nucleus; C, cytoplasm.
  • The authors further noted that FISSEQ appears to be sensitive to genes associated with cell type and function, and this in turn could be used for cell typing. It was also speculated that FISSEQ might allow for a combined transcriptome profiling and mutation detection in situ.
  • *Abstract from Science 2014, Vol. 343:1360–1363

    Understanding the spatial organization of gene expression with single-nucleotide resolution requires localizing the sequences of expressed RNA transcripts within a cell in situ. Here, we describe fluorescent in situ RNA sequencing (FISSEQ), in which stably cross-linked complementary DNA (cDNA) amplicons are sequenced within a biological sample.
    Using 30-base reads from 8102 genes in situ, we examined RNA expression and localization in human primary fibroblasts with a simulated wound-healing assay. FISSEQ is compatible with tissue sections and whole-mount embryos and reduces the limitations of optical resolution and noisy signals on single-molecule detection. Our platform enables massively parallel detection of genetic elements, including gene transcripts and molecular barcodes, and can be used to investigate cellular phenotype, gene regulation, and environment in situ.
Anton Simeonov, Ph.D., works at the NIH.

ASSAY & Drug Development Technologies, published by Mary Ann Liebert, Inc., offers a unique combination of original research and reports on the techniques and tools being used in cutting-edge drug development. The journal includes a "Literature Search and Review" column that identifies published papers of note and discusses their importance. GEN presents here one article that was analyzed in the "Literature Search and Review" column, a paper published in Science titled "Highly multiplexed subcellular RNA sequencing in situ." Authors of the paper are Lee JH, Daugharthy ER, Scheiman J, Kalhor R, Yang JL, Ferrante TC, Terry R, Jeanty SS, Li C, Amamoto R, Peters DT, Turczyk BM, Marblestone AH, Inverso SA, Bernard A, Mali P, Rios X, Aach J, and Church GM.

MoBiTec, Germany, Announces Availability of Human Herpesvirus-6 (HHV-6) Assay Kits

Human herpesvirus (HHV-) 6 has been associated with various neurological diseases, including encephalitis, meningitis, epilepsy, and multiple sclerosis. MoBiTec partners with VIDIA, Czech Republic, to offer HHV-6 assay kits worldwide.

ELISA-VIDITEST and IF-VIDITEST anti-HHV-6 kits are intended for serological diagnosis of diseases associated with HHV–6 infection, such as exanthema subitum, acute respiratory illnesses, diarrhoea with fever and febrile seizures in infants, heterophile antibody-negative infectious mononucleosis in children, also interstitial pneumonia, encephalitis, meningitis, hepatitis, and aplastic anemia in immunodeficient patients. The presence of IgG anti-HHV-6 antibody reveals the immune status of the patient. Seroconversion or 4–fold rise in antibody titer in paired serum samples, taken in acute and convalescent phase of the infection, is indicative of an active infection.

Why use ELISA-VIDITEST and IF-VIDITEST anti-HHV-6?

• Herpesvirus IgG and IgM determination
• High sensitivity/specificity
• Unified incubation times for IgG and IgM determination
• IF assays available for confirmation of the results
• IgG determination in serum and cerebrospinal fluids
• Ready-to-use controls and conjugates
• Incubation at laboratory temperature

Overview on HHV-6 assay kits

ELISA-VIDITEST

• ODZ-235: anti-HHV-6 IgG; ELISA; semiquantitative
• ODZ-344: anti-HHV-6 IgG (CSF); ELISA; quantitative
• ODZ-345: anti-HHV-6 IgM; ELISA; semiquantitative

IF-VIDITEST

• ODZ-061: anti-HHV-6 IgG; IF; semiquantitative

» IF-VIDITEST anti-HHV-6 IgG is an indirect immunofluorescence assay for the detection of IgG antibodies to human herpesvirus type 6 (HHV-6). «

For more information about the ELISA-VIDITEST and IF-VIDITEST anti-HHV-6 kits, please visit http://www.mobitec.com/cms/products/bio/08_screening/hhv_assay_kits.html.

About MoBiTec

MoBiTec GmbH (Goettingen, Germany) is a privately held company (founded in 1987) that offers research tools for molecular and cell biology. Products include DNA vectors for cloning and expression, cell transfection reagents and cell culture tools, immobilized and soluble enzymes, products for genomics and proteomics research, numerous antibodies and recombinant proteins, superior fluorescence reagents and kits, affinity chromatography products, as well as general laboratory equipment.

In parallel to its own product lines, MoBiTec distributes products from international companies in Germany. MoBiTec products are distributed worldwide, in Germany from their home office, in other countries by distributors.